180 related articles for article (PubMed ID: 18432029)
21. What is the outcome of RA in 2011 and can we predict it?
Verstappen SM; Symmons DP
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):485-96. PubMed ID: 22137919
[TBL] [Abstract][Full Text] [Related]
22. Early rheumatoid arthritis.
Machold KP; Nell V; Stamm T; Aletaha D; Smolen JS
Curr Opin Rheumatol; 2006 May; 18(3):282-8. PubMed ID: 16582693
[TBL] [Abstract][Full Text] [Related]
23. Progression in early rheumatoid arthritis.
Combe B
Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):59-69. PubMed ID: 19233046
[TBL] [Abstract][Full Text] [Related]
24. Drug management of early rheumatoid arthritis - 2008.
Sokka T; Mäkinen H
Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):93-102. PubMed ID: 19233049
[TBL] [Abstract][Full Text] [Related]
25. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
26. Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond.
Kooloos WM; Wessels JA; van der Kooij SM; Allaart CF; Huizinga TW; Guchelaar HJ
Ann Rheum Dis; 2009 Aug; 68(8):1371. PubMed ID: 19605746
[No Abstract] [Full Text] [Related]
27. Assessment and management of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
[TBL] [Abstract][Full Text] [Related]
28. [Methotrexate: mainstay of rheumatoid arthritis treatment].
Jacobs JW; Bijlsma JW
Ned Tijdschr Geneeskd; 2009; 153():A879. PubMed ID: 19785862
[TBL] [Abstract][Full Text] [Related]
29. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression.
Haroon N; Srivastava R; Misra R; Aggarwal A
J Rheumatol; 2008 Jun; 35(6):975-8. PubMed ID: 18464312
[TBL] [Abstract][Full Text] [Related]
30. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
31. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
32. Are biologics more effective than classical disease-modifying antirheumatic drugs?
Nurmohamed MT; Dijkmans BA
Arthritis Res Ther; 2008; 10(5):118. PubMed ID: 18828888
[TBL] [Abstract][Full Text] [Related]
33. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
[TBL] [Abstract][Full Text] [Related]
34. [Treatment strategy for rheumatoid arthritis in Croatia].
Curković B
Reumatizam; 2008; 55(2):39-44. PubMed ID: 19024273
[TBL] [Abstract][Full Text] [Related]
35. The changing face of therapy for rheumatoid arthritis.
Kremer JM
Rheum Dis Clin North Am; 1995 Aug; 21(3):845-52. PubMed ID: 8619103
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of rheumatoid arthritis: 200 recommendations on the use of methotrexate].
Durand S
Perspect Infirm; 2009; 6(3):33-4. PubMed ID: 20120318
[No Abstract] [Full Text] [Related]
37. Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al.
Riksen NP; Rongen GA; Smits P; van Riel P; Barrera P
Arthritis Rheum; 2007 Feb; 56(2):694; author reply 694-5. PubMed ID: 17265507
[No Abstract] [Full Text] [Related]
38. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
[No Abstract] [Full Text] [Related]
39. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Martin Mola E; Pedersen R; Robertson D; Chang D; Koenig A; Freundlich B;
Ann Rheum Dis; 2009 Jul; 68(7):1113-8. PubMed ID: 18718986
[TBL] [Abstract][Full Text] [Related]
40. Early inflammatory arthritis versus rheumatoid arthritis.
Finckh A
Curr Opin Rheumatol; 2009 Mar; 21(2):118-23. PubMed ID: 19339921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
